S&P 500   2,472.65 (-4.33%)
DOW   21,025.66 (-4.07%)
QQQ   183.62 (-3.56%)
AAPL   243.49 (-4.25%)
FB   160.42 (-3.82%)
MSFT   152.91 (-3.04%)
GOOGL   1,109.47 (-4.52%)
AMZN   1,908.35 (-2.12%)
CGC   13.56 (-6.03%)
NVDA   251.96 (-4.42%)
BABA   187.19 (-3.75%)
MU   40.23 (-4.35%)
GE   7.19 (-9.33%)
TSLA   495.32 (-5.47%)
AMD   44.56 (-2.02%)
T   27.95 (-4.12%)
F   4.43 (-8.48%)
NFLX   362.34 (-3.50%)
BAC   19.76 (-6.97%)
GILD   72.89 (-2.50%)
PRI   83.89 (-5.69%)
DIS   94.73 (-1.94%)
S&P 500   2,472.65 (-4.33%)
DOW   21,025.66 (-4.07%)
QQQ   183.62 (-3.56%)
AAPL   243.49 (-4.25%)
FB   160.42 (-3.82%)
MSFT   152.91 (-3.04%)
GOOGL   1,109.47 (-4.52%)
AMZN   1,908.35 (-2.12%)
CGC   13.56 (-6.03%)
NVDA   251.96 (-4.42%)
BABA   187.19 (-3.75%)
MU   40.23 (-4.35%)
GE   7.19 (-9.33%)
TSLA   495.32 (-5.47%)
AMD   44.56 (-2.02%)
T   27.95 (-4.12%)
F   4.43 (-8.48%)
NFLX   362.34 (-3.50%)
BAC   19.76 (-6.97%)
GILD   72.89 (-2.50%)
PRI   83.89 (-5.69%)
DIS   94.73 (-1.94%)
S&P 500   2,472.65 (-4.33%)
DOW   21,025.66 (-4.07%)
QQQ   183.62 (-3.56%)
AAPL   243.49 (-4.25%)
FB   160.42 (-3.82%)
MSFT   152.91 (-3.04%)
GOOGL   1,109.47 (-4.52%)
AMZN   1,908.35 (-2.12%)
CGC   13.56 (-6.03%)
NVDA   251.96 (-4.42%)
BABA   187.19 (-3.75%)
MU   40.23 (-4.35%)
GE   7.19 (-9.33%)
TSLA   495.32 (-5.47%)
AMD   44.56 (-2.02%)
T   27.95 (-4.12%)
F   4.43 (-8.48%)
NFLX   362.34 (-3.50%)
BAC   19.76 (-6.97%)
GILD   72.89 (-2.50%)
PRI   83.89 (-5.69%)
DIS   94.73 (-1.94%)
S&P 500   2,472.65 (-4.33%)
DOW   21,025.66 (-4.07%)
QQQ   183.62 (-3.56%)
AAPL   243.49 (-4.25%)
FB   160.42 (-3.82%)
MSFT   152.91 (-3.04%)
GOOGL   1,109.47 (-4.52%)
AMZN   1,908.35 (-2.12%)
CGC   13.56 (-6.03%)
NVDA   251.96 (-4.42%)
BABA   187.19 (-3.75%)
MU   40.23 (-4.35%)
GE   7.19 (-9.33%)
TSLA   495.32 (-5.47%)
AMD   44.56 (-2.02%)
T   27.95 (-4.12%)
F   4.43 (-8.48%)
NFLX   362.34 (-3.50%)
BAC   19.76 (-6.97%)
GILD   72.89 (-2.50%)
PRI   83.89 (-5.69%)
DIS   94.73 (-1.94%)
Log in

NASDAQ:OPNT - Opiant Pharmaceuticals Stock Price, Forecast & News

$9.70
+0.12 (+1.25 %)
(As of 04/1/2020 04:00 PM ET)
Today's Range
$9.35
Now: $9.70
$9.70
50-Day Range
$9.00
MA: $11.33
$13.40
52-Week Range
$8.05
Now: $9.70
$18.23
Volume336 shs
Average Volume25,237 shs
Market Capitalization$41.13 million
P/E Ratio4.75
Dividend YieldN/A
Beta0.4
Opiant Pharmaceuticals, Inc., a specialty pharmaceutical company, develops pharmacological treatments for substance use, addictive and eating disorders. The company offers NARCAN nasal spray, a treatment to reverse opioid overdoses. Its pipeline of product candidates includes treatments for eating disorders, including bulimia nervosa and binge eating disorders, alcohol use disorders, a long term treatment to prevent relapse for patients with opioid use disorders, cocaine use disorders, and a heroin vaccine. Opiant Pharmaceuticals, Inc. has a collaboration agreement with Titan Pharmaceuticals, Inc. to explore development of a novel approach to the prevention of opioid relapse and overdose in individuals with opioid use disorder. The company was formerly known as Lightlake Therapeutics Inc. and changed its name to Opiant Pharmaceuticals, Inc. in January 2016. Opiant Pharmaceuticals, Inc. was founded in 2005 and is headquartered in Santa Monica, California. Opiant Pharmaceuticals, Inc. is a subsidiary of Pelikin Group.
Read More
Opiant Pharmaceuticals logo

Industry, Sector and Symbol

Industry Metal mining
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:OPNT
CUSIPN/A
Phone310-598-5410

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$40.52 million
Cash Flow$0.29 per share
Book Value$8.41 per share

Profitability

Net Income$11.59 million

Miscellaneous

Employees16
Market Cap$41.13 million
Next Earnings Date5/14/2020 (Estimated)
OptionableNot Optionable

Receive OPNT News and Ratings via Email

Sign-up to receive the latest news and ratings for OPNT and its competitors with MarketBeat's FREE daily newsletter.


Opiant Pharmaceuticals (NASDAQ:OPNT) Frequently Asked Questions

How has Opiant Pharmaceuticals' stock been impacted by COVID-19 (Coronavirus)?

Opiant Pharmaceuticals' stock was trading at $10.85 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, OPNT shares have decreased by 10.6% and is now trading at $9.70. View which stocks have been mosted impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Opiant Pharmaceuticals?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Opiant Pharmaceuticals in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Opiant Pharmaceuticals.

When is Opiant Pharmaceuticals' next earnings date?

Opiant Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Thursday, May 14th 2020. View our earnings forecast for Opiant Pharmaceuticals.

How were Opiant Pharmaceuticals' earnings last quarter?

Opiant Pharmaceuticals Inc (NASDAQ:OPNT) posted its quarterly earnings results on Wednesday, March, 4th. The technology company reported $0.20 EPS for the quarter, missing the Thomson Reuters' consensus estimate of $0.31 by $0.11. The technology company had revenue of $7.67 million for the quarter, compared to the consensus estimate of $7.70 million. Opiant Pharmaceuticals had a net margin of 28.61% and a return on equity of 3.61%. View Opiant Pharmaceuticals' earnings history.

What price target have analysts set for OPNT?

1 brokerages have issued twelve-month price targets for Opiant Pharmaceuticals' shares. Their forecasts range from $42.00 to $42.00. On average, they expect Opiant Pharmaceuticals' share price to reach $42.00 in the next twelve months. This suggests a possible upside of 333.0% from the stock's current price. View analysts' price targets for Opiant Pharmaceuticals.

Has Opiant Pharmaceuticals been receiving favorable news coverage?

Media coverage about OPNT stock has been trending very negative on Wednesday, InfoTrie reports. The research firm ranks the sentiment of media coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Opiant Pharmaceuticals earned a news impact score of -3.3 on InfoTrie's scale. They also gave media coverage about the technology company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an impact on the company's share price in the near term. View the latest news aboutOpiant Pharmaceuticals.

Are investors shorting Opiant Pharmaceuticals?

Opiant Pharmaceuticals saw a decrease in short interest in March. As of March 13th, there was short interest totaling 4,800 shares, a decrease of 30.4% from the February 27th total of 6,900 shares. Based on an average daily volume of 27,500 shares, the days-to-cover ratio is currently 0.2 days. Approximately 0.1% of the shares of the company are sold short. View Opiant Pharmaceuticals' Current Options Chain.

Who are some of Opiant Pharmaceuticals' key competitors?

What other stocks do shareholders of Opiant Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Opiant Pharmaceuticals investors own include AcelRx Pharmaceuticals (ACRX), Cara Therapeutics (CARA), Vodafone Group (VOD), Synchrony Financial (SYF), Cyberark Software (CYBR), AT&T (T), Vodafone Group (VOD), Corbus Pharmaceuticals (CRBP), Cronos Group (CRON) and Agenus (AGEN).

Who are Opiant Pharmaceuticals' key executives?

Opiant Pharmaceuticals' management team includes the following people:
  • Dr. Roger Crystal, CEO & Director (Age 43)
  • Mr. David D. O'Toole, Chief Financial Officer (Age 60)
  • Dr. Phil Skolnick, Chief Scientific Officer (Age 72)
  • Mr. Kevin Andrew Pollack Esq., J.D., M.B.A., Advisor (Age 49)
  • Mr. Quan Vu, VP of Corp. Devel.

What is Opiant Pharmaceuticals' stock symbol?

Opiant Pharmaceuticals trades on the NASDAQ under the ticker symbol "OPNT."

How do I buy shares of Opiant Pharmaceuticals?

Shares of OPNT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Opiant Pharmaceuticals' stock price today?

One share of OPNT stock can currently be purchased for approximately $9.70.

How big of a company is Opiant Pharmaceuticals?

Opiant Pharmaceuticals has a market capitalization of $41.13 million and generates $40.52 million in revenue each year. The technology company earns $11.59 million in net income (profit) each year or $0.20 on an earnings per share basis. Opiant Pharmaceuticals employs 16 workers across the globe. View additional information about Opiant Pharmaceuticals.

What is Opiant Pharmaceuticals' official website?

The official website for Opiant Pharmaceuticals is http://www.opiant.com/.

How can I contact Opiant Pharmaceuticals?

Opiant Pharmaceuticals' mailing address is 233 WILSHIRE BLVD. SUITE 280, SANTA MONICA CA, 90401. The technology company can be reached via phone at 310-598-5410 or via email at [email protected]


MarketBeat Community Rating for Opiant Pharmaceuticals (NASDAQ OPNT)

Community Ranking:  2.4 out of 5 (star star)
Outperform Votes:  258 (Vote Outperform)
Underperform Votes:  279 (Vote Underperform)
Total Votes:  537
MarketBeat's community ratings are surveys of what our community members think about Opiant Pharmaceuticals and other stocks. Vote "Outperform" if you believe OPNT will outperform the S&P 500 over the long term. Vote "Underperform" if you believe OPNT will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 4/1/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel